FOLH1 and neoplasm: However, more tumours could be suitable if BgRT is delivered after LuPSMA cycles for all nSUV thresholds considered with margin expansion of 10 mm/20 mm, due to the assumption that LuPSMA treatment would completely eliminate PSMA-positive regions.